Quality assessment of various brands of losartan potassium tablets sold in Uyo Metropolis


  • Arnold C. Igboasoiyi Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, University of Uyo, Uyo, Akwa Ibom State, Nigeria
  • Amarachi P. Egeolu Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, University of Calabar, Calabar, Cross River State, Nigeria.
  • Isaac E. Memberr Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, University of Uyo, Uyo, Akwa Ibom State, Nigeria


Angiotensin II receptor antagonist, AT1 receptor, Assay, losartan potassium


Background: Losartan potassium is a non-peptide angiotensin II receptor antagonist with high affinity and
selectivity for the AT1 receptor, used for the management of hypertension, diabetic nephropathy as well as
hypertension with left ventricular hypertrophy. Various brands of Losartan potassium were assayed to reveal their
conformity with compendia requirements and assure that the brands are of acceptable standards for human
Methods: Qualitative and quantitative analyses of ten (10) brands coded A-J of Losartan potassium sold in Uyo
metropolis were carried out using standard physical and ultraviolet (UV) spectrophotometric methods
Results: All the brands tested met the official requirements for uniformity of weight. Brand I failed the
disintegration test by British Pharmacopeia specification (disintegration within15 mins.) but conformed to the
United States Pharmacopeia specification (disintegrated within 30 mins.). Only brand J complied with official
dissolution specification (>80% at 30 mins.) when 0.1 N HCl was used as the dissolution medium, whereas, all
the brands except brand F (<80%) complied when distilled water was used. The calibration curve for reference
Losartan potassium in methanol was linear over a concentration range of 0.00-50 µg/mL with correlation
coefficient of 0.985. All the brands passed the British Pharmacopoeia (BP) and United States Pharmacopoeia
(USP) requirements for percentage drug content of 98.5% to 101.5% and 95.0% to 105.0% respectively.
Conclusion: The brands performed creditably well in their physical characteristics and percentage recoveries. The
assay method in this study was simple, inexpensive, and reproducible and can be routinely used to assay Losartan
potassium tablets.


Al-Majed ARA, Assiri E, Khalil NY, Abdel-Aziz HA. Losartan: comprehensive profile. Profiles of Drug

Substances, Excipients and Related Methodology 2015; 40:159-194.

Andersen S, Rossing P, Juhl TR, Deinum J, Parving, HH. (). Optimal dose of losartan for renoprotection in

diabetic nephropathy. Nephrology Dialysis Transplantation 2002; 17(8):1413-1418.

Gao, J., Wang, X., Song, W., Wang, Y. and Xiao, Y. Dysglycemia and Dyslipidemia Models in Nonhuman

Primates: Part V. Diabetic Nephropathy and Effects of Angiotensin Ⅱ Receptor 06, 2022.

Bartko PE, Dal-Bianco JP, Antagonist Losartan. 2022 Journal of Diabetes and Metabolism (Open Access).

Retrieved, April Guerrero JL, Beaudoin J, Szymanski C, Kim DH, Seybolt MM, Handschumacher MD, Sullivan

S, Garcia ML, Titus JS. Effect of losartan on mitral valve changes after myocardial infarction. Journal of the

American College of Cardiology 2017; 70(10):1232-1244.

AAFP. Losartan Does More Than Lower Blood Pressure. American Family Physician 2002; 66(5):865-866.

Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A,

Sugisaki T, Suzuki H, Umemura S, Kawaguchii Y, Uchida S, Kuwahara M, Yamazaki T. Renoprotective effect

of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the

Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients JLIGHT),

Hypertens Res 2004; 27(1):21-30.

Hameed A, Naveed S, Abbas S, Qamar F. Pharmaceutical equivalent study of losartan potassium formulation

available in Karachi, Pakistan. Journal of Bioequivalence and Bioavailability 2016; 8(6):283-284.

Lam M, Beqo A, Thumar R. Overcoming Cough and Angioedema: Advocating for the Use of ARBs over

ACE Inhibitors. Annals of Pharmacotherapy, https://doi.org/10.1177/10600280211029952. Retrieved, April 10,

Igboasoiyi AC, Offor AC, Egeolu AP. Quality Assessment of various Brands of Ciprofloxacin Hydrochloride

Tablets sold in Uyo metropolis, Nigerian Journal of Pharmaceutical and Applied Science Research 2018;


Ubajaka CF, Obi-Okaro AC, Emelumadu OF, Azumarah MN, Ukegbu AU, Ilikannu SO. Factors

Associated with Drug Counterfeit in Nigeria: A Twelve Year Review. British Journal of Medicine & Medical

Research 2016; 12(4):1-8. Article no.BJMMR.21342 ISSN: 2231-0614, NLM ID: 101570965

SCIENCEDOMAIN international www.sciencedomain.org

Adegbolagun OA, Olalade OA, Osumah SE. Comparative evaluation of the biopharmaceutical and chemical

equivalence of some commercially available brands of lisinopril hydrochloride tablets. Tropical Journal of

Pharmaceutical Research, 2007; 6:737-745.

British Pharmacopoeia (2013). Safety data sheet. Article 31: version number 2, London 2013. 4p [13]

United States Food and Drug Administration, Center for Drug Evaluation and Research Guidance for Industry:

Dissolution testing of immediate release solid oral dosage forms, 1997; available at:


United States Pharmacopoeia and National Formulary USP-24 NF-19 (2014). The United States

Pharmacopoeia Convention Inc. Rockville, M.D., 2014.1890-1891pp

Sultana MM. Performance Evaluation of Losartan Potassium Tablets of five different Pharmaceutical

Companies in Bangladesh, Daffodil International University Library. Daffodil 2017. 22-23pp

British Pharmacopoeia. British Pharmacopeia. Her Majesty Stationary Press, London 2009. 1163p

Jantratid E, Janssen N, Reppas C, Dressma J. Dissolution Media Simulation Conditions in the Proximal

Human Gastrointestinal Tract: AnUpdate. Pharmaceutical Resources 2008. 25:1663-1676.

Guidance for Industry: Immediate Release Solid oral Dosage Forms, Scale-Up and Post Approval Changes:

Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence

Documentation. Rockville, MD, USA, US Food and Drug Administration, 1995.

British Pharmacopoeia. Medicines and Health Product Regulatory Agency, Volume II, London 2015. 136p




How to Cite

C. Igboasoiyi, A., P. Egeolu, A., & E. Memberr, I. (2022). Quality assessment of various brands of losartan potassium tablets sold in Uyo Metropolis. Journal of Drug Discovery and Research, 1(1), 36–43. Retrieved from https://ddrg.net/index.php/ddrg/article/view/9

Most read articles by the same author(s)